Tofacitinib versus Biologic Treatments in Moderate-to-Severe Rheumatoid Arthritis Patients Who Have Had an Inadequate Response to Nonbiologic DMARDs: Systematic Literature Review a...

by Evelien Bergrath, Robert A. Gerber, David Gruben, Tatjana Lukic, Charles Makin, Gene Wallenstein
Published 2017-01-01

Associations between Patient Global Assessment scores and pain, physical function, and fatigue in rheumatoid arthritis: a post hoc analysis of data from phase 3 trials of tofacitin...

by Vibeke Strand, Jeffrey Kaine, Rieke Alten, Gene Wallenstein, Annette Diehl, Harry Shi, Rebecca Germino, Christopher W. Murray
Published 2020-10-01

Real-World Comparative Effectiveness of Tofacitinib and Tumor Necrosis Factor Inhibitors as Monotherapy and Combination Therapy for Treatment of Rheumatoid Arthritis

by George W. Reed, Robert A. Gerber, Ying Shan, Liza Takiya, Kimberly J. Dandreo, David Gruben, Joel Kremer, Gene Wallenstein
Published 2019-11-01